Evidence map›Paper›PMID 38649147›Full record

ArticleBMB reports2024

ASCL1-mediated direct reprogramming: converting ventral midbrain astrocytes into dopaminergic neurons for Parkinson's disease therapy.

Sang Hui Yong, Sang-Mi Kim, Gyeong Woon Kong, Seung Hwan Ko, Eun-Hye Lee, Yohan Oh, Chang-Hwan Park

Open access · goldAbstract read
PubMed Full text at PMC
In one paragraph

Article in BMB reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sang Hui YongGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Sang-Mi KimHanyang Biomedical Research Institute, Hanyang University, Seoul 04763; Center for Embryo and Stem Cell Research, CHA Advanced Research Institute, CHA University, Seongnam 13488, Korea.
Gyeong Woon KongGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Seung Hwan KoGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea.
Eun-Hye LeeNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Yohan OhGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763; Hanyang Biomedical Research Institute, Hanyang University, Seoul 04763; Department of Biochemistry and Molecular Biology, College of Medicine, Hanyang University, Seoul 04763; Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763; Hanyang Institute of Advanced BioConvergence, Hanyang University, Seoul 04763, Korea.
Chang-Hwan ParkGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763; Hanyang Biomedical Research Institute, Hanyang University, Seoul 04763, Korea.
Hanyang University · KRCHA University · KRJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD), characterized by dopaminergic neuron degeneration in the substantia nigra, is caused by various genetic and environmental factors. Current treatment methods are medication and surgery; however, a primary therapy has not yet been proposed. In this study, we aimed to develop a new treatment for PD that induces direct reprogramming of dopaminergic neurons (iDAN). Achaete-scute family bHLH transcription factor 1 (ASCL1) is a primary factor that initiates and regulates central nervous system development and induces neurogenesis. In addition, it interacts with BRN2 and MYT1L, which are crucial transcription factors for the direct conversion of fibroblasts into neurons. Overexpression of ASCL1 along with the transcription factors NURR1 and LMX1A can directly reprogram iDANs. Using a retrovirus, GFP-tagged ASCL1 was overexpressed in astrocytes. One week of culture in iDAN convertsion medium reprogrammed the astrocytes into iDANs. After 7 days of differentiation, TH+/TUJ1+ cells emerged. After 2 weeks, the number of mature TH+/TUJ1+ dopaminergic neurons increased. Only ventral midbrain (VM) astrocytes exhibited these results, not cortical astrocytes. Thus, VM astrocytes can undergo direct iDAN reprogramming with ASCL1 alone, in the absence of transcription factors that stimulate dopaminergic neurons development. [BMB Reports 2024; 57(8): 363-368].

Indexed as

AstrocytesBasic Helix-Loop-Helix ProteinsCellular ReprogrammingDopaminergic NeuronsMesencephalonNuclear Receptor Subfamily 4, Group A, Member 2Parkinson DiseaseTranscription FactorsAnimalsCell DifferentiationCells, CulturedHumansLIM-Homeodomain ProteinsMiceNerve Tissue ProteinsNeurogenesisAscl1 protein, mouseBasic Helix-Loop-Helix ProteinsLIM-Homeodomain ProteinsLmx1a protein, mouseMyt1l protein, mouseNerve Tissue ProteinsNr4a2 protein, mouseNuclear Receptor Subfamily 4, Group A, Member 2Transcription Factors

Identifiers

PMID38649147
PMCPMC11362138
OpenAlexW4394909494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.